JAVIER
PUENTE VÁZQUEZ
Profesor asociado de Ciencias de la Salud
Hospital Universitario Virgen del Rocío
Sevilla, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Virgen del Rocío (20)
2024
-
Criteria and indicators to evaluate quality of care in genitourinary tumour boards
Clinical and Translational Oncology
2023
-
A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide
Prostate, Vol. 83, Núm. 4, pp. 376-384
-
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis
Future Oncology, Vol. 19, Núm. 12, pp. 819-828
-
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial
Clinical and Translational Oncology
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
-
Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management
Critical Reviews in Oncology/Hematology, Vol. 174
2019
-
Prorepair-B: A prospective cohort study of the impact of germline DNA repair mutations on the outcomes of patients with metastatic castration-resistant prostate cancer
Journal of Clinical Oncology, Vol. 37, Núm. 6, pp. 490-503
-
The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
Targeted Oncology, Vol. 14, Núm. 1, pp. 15-32
2018
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
2017
-
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: A multi-institution correlative biomarker study
Annals of Oncology, Vol. 28, Núm. 7, pp. 1-9
-
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions
Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 341-356
-
Erratum to: Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions (Clin Transl Oncol, 10.1007/s12094-016-1535-8)
Clinical and Translational Oncology
-
Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial
The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
-
Recent advances in genitourinary tumors: A review focused on biology and systemic treatment
Critical Reviews in Oncology/Hematology, Vol. 113, pp. 171-190
-
The role of mTOR inhibition as second-line therapy in metastatic renal carcinoma: clinical evidence and current challenges
Expert Review of Anticancer Therapy, Vol. 17, Núm. 3, pp. 217-226
2016
2014
-
Erratum to: Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer (Targeted Oncology (2014) 9, (9-24) DOI: 10.1007/s11523-013-0304-7)
Targeted Oncology
-
Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer
Targeted Oncology, Vol. 9, Núm. 1, pp. 9-24
-
SEOM clinical guidelines for the treatment of renal cell carcinoma
Clinical and Translational Oncology, Vol. 16, Núm. 12, pp. 1043-1050